$69M ChemoCentryx Investor Securities Settlement, Check If You Qualify for a Payment

Prepared by the AllAboutLawyer.com Editorial Team, reviewed for factual accuracy against official court records and the settlement administrator website on May 18, 2026. Last Updated: May 18, 2026.

The ChemoCentryx investor securities settlement is a class action lawsuit where eligible investors who bought ChemoCentryx stock between November 26, 2019 and May 6, 2021 can receive a payment by filing a claim before the deadline posted at chemocentryxsecuritieslitigation.com. Amgen Inc.’s ChemoCentryx Inc. will pay $69 million to settle investor class allegations that it overhyped the safety of its drug to treat severe vasculitis. The pension fund leading the case filed for preliminary approval of the increased settlement on May 15, 2026 before Judge Jon S. Tigar in the U.S. District Court for the Northern District of California. The settlement is awaiting court approval — no claim form is open yet.

Quick-Facts

Field	Detail
Settlement Amount	$69,000,000
Claim Deadline	TBD — claim portal not yet open; monitor chemocentryxsecuritieslitigation.com
Who Qualifies	Investors who purchased ChemoCentryx common stock November 26, 2019 – May 6, 2021
Payout Per Person	TBD — determined by pro-rata calculation based on number of valid claims after final court approval
Proof Required	Yes — brokerage statements and trade confirmations showing transactions during the class period
Settlement Status	Preliminary approval pending before Judge Jon S. Tigar
Administrator	Kroll Settlement Administration, P.O. Box 5013, New York, NY 10150-5013 · 833-522-2606
Official Website	chemocentryxsecuritieslitigation.com
Last Updated	May 18, 2026

Current Status

• Preliminary approval motion was filed May 15, 2026 before Judge Jon S. Tigar in the Northern District of California.
• The settlement was nearly doubled from $35 million after the FDA’s Center for Drug Evaluation and Research proposed withdrawing regulatory approval for Tavneos, finding it hasn’t shown to be effective and that the drugmaker’s application contained untrue statements.
• No claim form is open yet — investors should register their contact information at the official site to receive notice when the claim portal opens.

What Is the ChemoCentryx Lawsuit About? Homyk v. ChemoCentryx, Inc. et al., No. 4:21-cv-03343-JST

ChemoCentryx, the $3.7 billion biotech bought by Amgen in 2022, allegedly ignored repeated warnings from a data monitoring committee and withheld or manipulated trial results on the firm’s drug Tavneos, according to the investor lawsuit. The lawsuit alleges violations of Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 — federal laws that prohibit companies from making false or misleading statements that cause investors to pay artificially inflated prices for stock.

ChemoCentryx’s stock price rose sharply from late 2019 to early 2021, driven by positive readouts from the Phase 3 Advocate trial for Tavneos (avacopan) in a rare autoimmune disease called ANCA-associated vasculitis. During that period, then-CEO Thomas Schall sold about $40 million worth of ChemoCentryx shares. Investors say the company told the public everything was going smoothly with the FDA while concealing serious concerns about the drug’s safety and trial data.

According to the plaintiffs, the data monitoring committee for the Advocate trial repeatedly warned ChemoCentryx that its public communications understated the liver toxicity risks associated with Tavneos. In a March 2021 letter, the committee requested immediate corrective action and that prior records be shared with the FDA. Plaintiffs allege that Schall did not act on the committee’s request. When the FDA finally disclosed its safety concerns publicly, the stock dropped more than 45% in a single day, wiping out investors who bought shares during the class period. If you have followed similar pharma investor cases, the Celgene $239 million securities class action settlement involved similar allegations of misrepresenting drug prospects to investors.

The FDA’s position has only hardened. The FDA’s Center for Drug Evaluation and Research is now proposing to withdraw approval of Tavneos entirely, stating the ADVOCATE study did not provide reliable evidence of the effectiveness of Tavneos. That development directly pushed the lead plaintiff to renegotiate the settlement upward from $35 million to $69 million.

Related article: Citizens Bank Data Breach Class Action Lawsuit, Were You a Customer When the Everest Hack Hit?

Who Qualifies for the ChemoCentryx Investor Securities Settlement?

If you are wondering whether the do I qualify for the ChemoCentryx settlement question applies to you, the eligibility test is straightforward.

You may qualify if:

• You purchased or otherwise acquired ChemoCentryx, Inc. common stock on or after November 26, 2019
• You held that stock through at least one date when corrective disclosures caused the price to fall — on or before May 6, 2021
• You suffered financial damages as a result — meaning you paid more for the stock than it was actually worth because of the alleged misrepresentations

You do NOT qualify if:

• You purchased ChemoCentryx shares before November 26, 2019
• You purchased shares after May 6, 2021
• You are one of the persons excluded from the Class by definition, as discussed in the official Notice issued by Kroll Settlement Administration (this typically includes the defendants, their immediate family members, and company officers and directors)
• You submitted a request for exclusion postmarked by January 14, 2025 — that deadline has passed, meaning you can no longer opt out

The class action settlement eligibility here covers investors with brokerage accounts at any firm, including retirement accounts such as IRAs, 401(k)s, and pension funds. Institutional investors and individual retail investors are both included. For comparison on how similar pharma-sector investor settlements handled eligibility, see the Catalent $78 million securities class action settlement.

How Much Can You Get from the ChemoCentryx Settlement?

The total settlement fund is $69,000,000. Your individual legal settlement payout depends on a pro-rata calculation — meaning the fund gets divided among all valid claimants based on each person’s recognized loss amount relative to everyone else’s combined losses.

The settlement covers a class of more than 35,000 investors who acquired ChemoCentryx stock between November 2019 and May 2021. With 35,000+ investors sharing $69 million, the raw average is roughly $1,971 per investor — but your actual compensation for damages will be higher or lower depending on how many shares you held, the prices you paid, and when you sold.

The exact per-share calculation, including the Plan of Allocation, has not yet been released publicly. It will be posted on chemocentryxsecuritieslitigation.com once the court grants preliminary approval and the claim portal opens. Attorney fees and administrative costs will also be deducted before distribution.

Step-by-Step: How to File Your ChemoCentryx Claim Form

No claim form is open at this time — the settlement is still awaiting preliminary approval. When the portal opens, here is how to file a class action settlement claim:

1. Visit chemocentryxsecuritieslitigation.com and click the claim filing link
2. Enter your full name, address, and taxpayer identification information
3. Identify all ChemoCentryx stock transactions made between November 26, 2019 and May 6, 2021
4. Upload your brokerage statements, trade confirmations, or authorized account statements showing your purchases, sales, and holdings
5. Submit your completed claim form online — or mail it to Kroll Settlement Administration, P.O. Box 5013, New York, NY 10150-5013
6. Save your confirmation number and a copy of all documents submitted

Estimated time to complete: 15–30 minutes, depending on how many transactions you need to document.

ChemoCentryx Settlement Key Dates

Milestone	Date
Lawsuit Originally Filed	May 2021
Class Period	November 26, 2019 – May 6, 2021
Class Certified	2024
Exclusion Deadline	January 14, 2025 (passed)
$35M Settlement Filed for Preliminary Approval	March 13, 2026
Increased $69M Settlement Filed	May 15, 2026
Preliminary Approval Hearing	TBD — pending before Judge Jon S. Tigar
Claim Filing Deadline	TBD — claim portal not yet open
Objection Deadline	TBD — pending preliminary approval order
Final Approval Hearing	TBD — to be scheduled after preliminary approval
Expected Payment Date	TBD — estimated several months after final court approval

Frequently Asked Questions

Is there a class action lawsuit against ChemoCentryx?

 Yes. This is a securities fraud class action on behalf of persons who purchased ChemoCentryx common stock between November 26, 2019 and May 6, 2021, filed in the U.S. District Court for the Northern District of California, Case No. 4:21-cv-03343-JST. A $69 million settlement has been negotiated and is currently awaiting preliminary court approval.

Do I need a lawyer to file a claim? 

No. Class action settlement claims do not require you to hire your own attorney. Bernstein Litowitz Berger & Grossmann LLP represents the class. However, if you suffered very large losses and are considering pursuing an individual claim instead, you should consult a class action lawsuit attorney or consumer rights lawyer before the settlement becomes final.

Is this settlement legitimate? 

Yes. The settlement is administered by Kroll Settlement Administration, a court-supervised firm, under the authority of the U.S. District Court for the Northern District of California. The only authorized website for this case is chemocentryxsecuritieslitigation.com.

When will I receive my ChemoCentryx settlement payment?

 No payment date has been set yet. The $69 million settlement still requires preliminary approval from Judge Jon S. Tigar, then a final approval hearing, then processing of all valid claims by Kroll. Realistically, payments are unlikely before late 2026 or 2027 depending on the court schedule and any appeals.

What if I missed the ChemoCentryx claim deadline?

 The claim portal is not yet open, so no one has missed the claim deadline. The exclusion deadline of January 14, 2025 has passed, meaning you can no longer opt out. Monitor chemocentryxsecuritieslitigation.com for the filing deadline once preliminary approval is granted.

Will this settlement payment affect my taxes?

 Possibly. Securities fraud settlement payments that compensate for investment losses are treated differently by the IRS depending on your individual circumstances — some portions may be taxable income, while others may adjust your cost basis. Consult a tax advisor for advice specific to your situation before you file your return in the year you receive payment.

How did the FDA’s Tavneos withdrawal proposal affect the settlement amount?

 Directly. The pension fund leading the case nearly doubled the settlement price from $35 million to $69 million after the FDA’s Center for Drug Evaluation and Research proposed withdrawing regulatory approval for Tavneos, finding it hasn’t shown to be effective and that the drugmaker’s application contained untrue statements. This new FDA action significantly strengthened the investors’ position.

How do I know how many ChemoCentryx shares I held during the class period?

 Log into your brokerage account and pull statements covering November 2019 through May 2021. If you have switched brokerages, contact your former broker to request historical records. You will need these documents to support your claim — self-created spreadsheets or screenshots without account owner identification are generally not accepted.

Sources & References

• Official Case Website: chemocentryxsecuritieslitigation.com (Kroll Settlement Administration, court-authorized)
• Court Docket: Homyk v. ChemoCentryx, Inc. et al., Case No. 4:21-cv-03343-JST, U.S. District Court for the Northern District of California
• Federal Register: FDA Proposal to Withdraw Tavneos Approval, April 30, 2026

Disclaimer: This article is for informational purposes only and does not constitute legal advice. Legal claims and outcomes depend on specific facts and applicable law. For advice regarding your particular situation, consult a qualified attorney.